1-4 of 4
Shiro Kataoka
Close
Sort by
Journal Articles

In vivo efficacy of anti-MPL agonist antibody in promoting primary human hematopoietic cells

Brief Report
Masayuki Kai, Tetsuya Hagiwara, Chie Emuta, Yukiko Chisaka, Kumi Tsuruhata, Chisato Endo, Yoshimasa Inagaki, Hiroshi Miyazaki, Shiro Kataoka
Journal: Blood
Blood (2009) 113 (10): 2213–2216.
https://doi.org/10.1182/blood-2008-10-184440
Published: 2009
Journal Articles

Domain Subclass Conversion Improved Activity of Anti-Mpl Agonist Antibodies in the Form of Whole IgG.

Masayuki Kai, PhD, Kazuhiro Motoki, Ph.D., Hideaki Yoshida, Ph.D., Kumi Tsuruhata, Chisato Endo, Mari Muto, Chie Emuta, Ph.D., Yukiko Chisaka, Munetake Shimabe, Hiroshi Miyazaki, Ph.D, Shiro Kataoka, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 1134.
https://doi.org/10.1182/blood.V108.11.1134.1134
Published: 2006
Journal Articles

Anti-Myeloma Activity of the Maytansinoid Immunoconjugate of Internalizing Human Monoclonal Antibody Specific for HM1.24/BST2 (CD317).

Shuji Ozaki, Takafumi Tomura, Etsuko Sekimoto, Yoichi Tanaka, Kenichi Kitazoe, Jin Asano, Toshihiro Hashimoto, Masahiro Abe, Takayuki Furuta, Tomoyuki Tahara, Isao Ishida, Shiro Kataoka, Toshio Matsumoto
Journal: Blood
Blood (2005) 106 (11): 3388.
https://doi.org/10.1182/blood.V106.11.3388.3388
Published: 2005
Journal Articles

Human Monoclonal Antibodies to TRAIL Receptors R1 and R2 Effectively Induce Apoptosis in Human Myeloma Cells.

Shuji Ozaki, MD, Etsuko Sekimoto, MD, Yoichi Tanaka, MD, Takashi Ohshima, MD, Hironobu Shibata, MD, Toshihiro Hashimoto, MD, Masahiro Abe, MD, Kazuhiro Motoki, PhD, Isao Ishida, PhD, Shiro Kataoka, PhD, Toshio Matsumoto, MD
Journal: Blood
Blood (2004) 104 (11): 3366.
https://doi.org/10.1182/blood.V104.11.3366.3366
Published: 2004